Related references
Note: Only part of the references are listed.Long non-coding RNAs: How to regulate the metastasis of non-small-cell lung cancer
Cheng Fang et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2020)
Long non-coding RNA PVT1 contributes to cell growth and metastasis in non-small-cell lung cancer by regulating miR-361-3p/SOX9 axis and activating Wnt/β-catenin signaling pathway
Guanbin Qi et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
The long non-coding RNA PVT1/miR-145-5p/ITGB8 axis regulates cell proliferation, apoptosis, migration and invasion in non-small cell lung cancer cells
C. M. Wei et al.
NEOPLASMA (2020)
The PVT1/miR-216b/Beclin-1 regulates cisplatin sensitivity of NSCLC cells via modulating autophagy and apoptosis
Liangfeng Chen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)
被撤回的出版物: miR-802 inhibits the aggressive behaviors of non-small cell lung cancer cells by directly targeting FGFR1 (Retracted article. See vol. 61, pg. 99, 2022)
Jiexia Zhang et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2019)
FGFR1 Induces Acquired Resistance Against Gefitinib By Activating AKT/mTOR Pathway In NSCLC
Dan Zhang et al.
ONCOTARGETS AND THERAPY (2019)
Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy
Lais Osmani et al.
SEMINARS IN CANCER BIOLOGY (2018)
Long non-coding RNA as potential biomarkers in non-small-cell lung cancer: What do we know so far?
Maria Aleksandra Osielska et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
Molecular mechanisms of lncRNA SMARCC2/miR-551b-3p/TMPRSS4 axis in gastric cancer
Hao Yuan et al.
CANCER LETTERS (2018)
Design, synthesis and biological evaluation of 4-bromo-N-(3,5-dimethoxyphenyl)benzamide derivatives as novel FGFR1 inhibitors for treatment of non-small cell lung cancer
Zixin Xie et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2018)
FGFR1-ERK1/2-SOX2 axis promotes cell proliferation, epithelial-mesenchymal transition, and metastasis in FGFR1-amplified lung cancer
Kaixuan Wang et al.
ONCOGENE (2018)
A novel FGFR1-binding peptide exhibits anti-tumor effect on lung cancer by inhibiting proliferation and angiogenesis
Qiaoyan Tan et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2018)
MicroRNAs as a drug resistance mechanism to targeted therapies in EGFR-mutated NSCLC: Current implications and future directions
Alessandro Leonetti et al.
DRUG RESISTANCE UPDATES (2018)
Understanding and targeting resistance mechanisms in NSCLC
Julia Rotow et al.
NATURE REVIEWS CANCER (2017)
lncRNA PVT1 in cancer: A review and meta-analysis
Dapeng Lu et al.
CLINICA CHIMICA ACTA (2017)
Downregulation of Foxo3 and TRIM31 by miR-551b in side population promotes cell proliferation, invasion, and drug resistance of ovarian cancer
Zhentong Wei et al.
MEDICAL ONCOLOGY (2016)
An eight-long non-coding RNA signature as a candidate prognostic biomarker for lung cancer
Zhenbo Tu et al.
ONCOLOGY REPORTS (2016)
MicroRNA expression profiles predict progression and clinical outcome in lung adenocarcinoma
Kang Lin et al.
ONCOTARGETS AND THERAPY (2016)
The clinical pathological characteristics and prognosis of FGFR1 gene amplification in non-small-cell lung cancer: a meta-analysis
Fa-Jun Xie et al.
ONCOTARGETS AND THERAPY (2016)
Share Paper
